07:48 AM EDT, 08/12/2025 (MT Newswires) -- Anavex Life Sciences ( AVXL ) reported a fiscal Q3 loss Tuesday of $0.16 per diluted share, wider than a loss of $0.14 a year earlier.

Analysts polled by FactSet expected a loss of $0.14.

As expected, the company did not report any revenue for the quarter.

As of June 30, the company said its cash and cash equivalents were $101.2 million, which, at current adjusted cash utilization rates, is expected to fund operations for more than three years.